Gottlieb A, Blauvelt A, Tha?i D, Poulin Y, Brock F, Arendt C, Boehnlein M, Reich K. Reductions in Absolute PASI Over 144 Weeks of Treatment with Certolizumab Pegol in Patients with Plaque Psoriasis: Pooled Analysis from Two Phase 3 Trials (CIMPASI-1 and CIMPASI-2). J of Skin [Internet]. 2020 Oct. 27 [cited 2024 Jul. 22];4(6):s84. Available from: https://jofskin.org/33014/index.php/skin/article/view/1117